Surgically debulked malignant pleural mesothelioma: Results and prognostic factors

Annals of Surgical Oncology

Volumn 4, Issue 3, 1997, Pages 215-222

  Pass, Harvey I ^a   Kranda, Karen ^a   Temeck, Barbara K ^a   Feuerstein, Irwin ^b   Steinberg, Seth M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Debulking; Mesothelioma; Prognostic factors; Surgery

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; IMMUNOTHERAPY; LUNG RESECTION; MALE; MESOTHELIOMA; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOTOTHERAPY; PLEURA TUMOR; POSTOPERATIVE COMPLICATION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK FACTOR; SURVIVAL; SURVIVAL RATE; UNITED STATES;

ADULT; AGED; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MESOTHELIOMA; MIDDLE AGED; PHOTOTHERAPY; PLEURAL NEOPLASMS; PNEUMONECTOMY; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; UNITED STATES;

EID: 0031115058     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02306613     Document Type: Article

References (12)

1. International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995;108:1122-8.
2. Pass HW, Temeck BK, Kranda K, Steinberg SM, Pass HI. A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction. Ann Surg Oncol 1995;2:214-20.
3. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
4. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep 1966;50:163-70.
5. Cox D. Regression models and lifetables. J R Stat Soc 1972;34:187-202.
6. Matthews DE, Farewell VT. Using and understanding medical statistics. Basel: Karger, 1985:148-58.
7. Jonckheere AR. A distribution-free K-sample test against ordered alternatives. Biometrika 1954;41:133-45.
8. Temeck BK, Pass HI. Esophagopleural fistula: a complication of photodynamic therapy. South Med J 1995;88:271-3.
9. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1991;102:1-9.
10. Pass HI, Pogrebniak HW. Malignant pleural mesothelioma. Curr Probl Surg 1993;30:921-1020.
11. Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma [Abstract]. Am Assoc Thorac Surg 1995;166.
12. Sugarbaker DJ, Lynch TJ, Strauss GM, et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 1993;11:1172-8.